9 citations
,
July 2023 in “Hypertension” This review highlights the association between gender-affirming hormone therapy and increased cardiovascular risk among transgender individuals, emphasizing the need for cardiovascular-focused clinical management and further research to inform and educate both clinicians and patients.
15 citations
,
September 2021 in “Frontiers in Endocrinology” This review discusses the impact of gender affirming hormone therapy on cardiovascular outcomes in transgender individuals and reports no new clinical results; the authors underscore the need for more comprehensive studies.
April 2020 in “Journal of the Endocrine Society” This study found that among transgender men undergoing long-term testosterone therapy, a severe pattern of androgenetic alopecia may indicate increased arterial stiffness, as measured by higher intima-media thickness of the carotid artery.
September 2024 in “Journal of the American Academy of Dermatology” This study aims to evaluate the prevalence of androgenetic alopecia in transgender men undergoing testosterone therapy, noting that such hormone treatment can lead to dermatological issues that significantly affect their quality of life. Results are not reported in the abstract.
October 2024 in “Journal of the Endocrine Society” This study found that feminizing hormone therapy increased GFR in transgender individuals assigned male at birth, suggesting an effect of sex hormones on kidney hemodynamics, while masculinizing therapy showed a slight, nonsignificant decrease in GFR.